SSX4抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P05363(SSX4 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The SSX4 antibody is designed to target the SSX4 protein, a member of the SSX (synovial sarcoma X breakpoint) family of cancer-testis antigens (CTAs). These proteins are typically expressed in immune-privileged germline tissues, such as the testis, but are aberrantly reactivated in various cancers, including melanoma, sarcoma, and certain carcinomas. SSX4. encoded by the *SSX4* gene on chromosome Xp11.2. shares structural homology with other SSX family members, featuring a conserved N-terminal domain and a divergent C-terminal region. Its expression is epigenetically regulated, often linked to DNA hypomethylation in malignancies.

SSX4 antibodies are primarily utilized in research to investigate the role of SSX4 in oncogenesis, particularly its involvement in modulating transcriptional regulation via interaction with polycomb-group proteins. These antibodies are critical tools for detecting SSX4 expression in tumor tissues through immunohistochemistry (IHC), Western blotting, or immunofluorescence, aiding in cancer biomarker studies. Additionally, SSX4's immunogenic properties make it a potential target for immunotherapy, as its ectopic expression in tumors may trigger immune responses. Commercial SSX4 antibodies are typically raised against recombinant protein fragments or synthetic peptides, validated for specificity across applications. Research on SSX4 continues to explore its diagnostic, prognostic, and therapeutic relevance in cancer biology.